Hearrt Failure
Conditions
Interventions
Group 1:dapagliflozin 10 mg + insulin
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Provide a signed and dated informed consent form; (2) Male or female, age = 18 years old; (3) Acute decompensation or acute new heart failure in chronic heart failure; (4) BNP or NT-pro BNP values are elevated; (5) Previously diagnosed as type 2 diabetes; (6) eGFR = 30mL / min / 1.73m3 at the time of registration; (7) Patients should receive standard background care for acute heart failure and follow local approved guidelines; (8) Subjects indicated willingness and completion of all steps and study intervention cycles in the study.
Exclusion criteria
Exclusion criteria: (1) receiving SGLT2 inhibitor treatment or previous intolerance to SGLT2 inhibitor within 8 weeks prior to enrollment; (2) implanting CRT 3 months ago or planning to implant CRT in the near future; (3) severe valvular disease; (4) Perform an orthotopic heart transplant or install a ventricular assist device within 12 months; (5) complex congenital heart disease; (6) Symptomatic bradycardia or second or third degree heart block without a pacemaker; (7) End-stage renal disease requiring replacement therapy; (8) Non-cardiogenic end-stage diseases with a predicted survival period of no more than 12 months; (9) pregnancy or planned pregnancy; (10) Failure to follow the research plan; (11) Other research projects that have been enrolled or planned to be enrolled; (12) Disagree to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac index;Intrathoracic blood volume;Extravascular lung water; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of other hemodynamic parameters;Fasting plasma glucose;BNP/NT-pro BNP;LVEF; | — |
Countries
China
Contacts
Public ContactMin Zhang
Shanghai Chest Hospital
Outcome results
None listed